Institutional Venture Management XV LLC Sells 2,625,000 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Institutional Venture Management XV LLC reduced its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 50.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,597,558 shares of the company's stock after selling 2,625,000 shares during the period. Hims & Hers Health makes up 35.9% of Institutional Venture Management XV LLC's holdings, making the stock its 2nd biggest position. Institutional Venture Management XV LLC owned 1.21% of Hims & Hers Health worth $52,445,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Arizona State Retirement System increased its stake in Hims & Hers Health by 3.0% during the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company's stock worth $815,000 after buying an additional 1,173 shares during the period. Belpointe Asset Management LLC lifted its position in Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company's stock valued at $118,000 after purchasing an additional 1,205 shares during the period. Victory Capital Management Inc. grew its position in Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company's stock worth $393,000 after buying an additional 1,212 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Finally, Swiss National Bank lifted its stake in Hims & Hers Health by 0.7% in the 1st quarter. Swiss National Bank now owns 281,500 shares of the company's stock valued at $4,355,000 after buying an additional 2,000 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $0.07 during midday trading on Wednesday, hitting $17.20. 3,312,301 shares of the stock traded hands, compared to its average volume of 7,713,728. The firm has a market capitalization of $3.69 billion, a PE ratio of -1,727.00 and a beta of 1.05. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74. The business's 50 day moving average price is $17.11 and its two-hundred day moving average price is $17.13.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period in the prior year, the business posted ($0.03) earnings per share. Hims & Hers Health's revenue was up 51.8% compared to the same quarter last year. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,335 shares of the company's stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total value of $47,353.80. Following the completion of the sale, the insider now directly owns 169,144 shares in the company, valued at $3,430,240.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Soleil Boughton sold 2,335 shares of the stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total value of $47,353.80. Following the completion of the sale, the insider now owns 169,144 shares in the company, valued at $3,430,240.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 11,609 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40. Following the sale, the chief financial officer now directly owns 181,469 shares in the company, valued at $2,649,447.40. The disclosure for this sale can be found here. Insiders sold 731,473 shares of company stock valued at $12,671,277 over the last three months. 17.71% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a "hold" rating in a research note on Wednesday, August 7th. Jefferies Financial Group boosted their price target on Hims & Hers Health from $14.00 to $23.00 and gave the company a "hold" rating in a research report on Thursday, June 27th. Piper Sandler restated a "neutral" rating and issued a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday, August 6th. Bank of America decreased their target price on Hims & Hers Health from $24.00 to $20.00 and set a "buy" rating for the company in a report on Friday, September 13th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an "outperform" rating to an "in-line" rating in a report on Friday, August 9th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $19.86.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.